Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1985 1
1986 1
1987 1
1988 1
1989 2
1990 2
1992 1
1993 2
1994 1
1995 3
1996 4
1997 3
1998 5
1999 4
2000 8
2001 12
2002 7
2003 11
2004 8
2005 20
2006 13
2007 10
2008 10
2009 15
2010 24
2011 15
2012 19
2013 18
2014 23
2015 26
2016 24
2017 29
2018 31
2019 35
2020 42
2021 34
2022 31
2023 29
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

476 results

Results by year

Filters applied: . Clear all
Page 1
European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barré syndrome.
van Doorn PA, Van den Bergh PYK, Hadden RDM, Avau B, Vankrunkelsven P, Attarian S, Blomkwist-Markens PH, Cornblath DR, Goedee HS, Harbo T, Jacobs BC, Kusunoki S, Lehmann HC, Lewis RA, Lunn MP, Nobile-Orazio E, Querol L, Rajabally YA, Umapathi T, Topaloglu HA, Willison HJ. van Doorn PA, et al. Eur J Neurol. 2023 Dec;30(12):3646-3674. doi: 10.1111/ene.16073. Epub 2023 Oct 10. Eur J Neurol. 2023. PMID: 37814552
To develop an evidence-based guideline for the diagnosis and treatment of GBS, using Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology a Task Force (TF) of the European Academy of Neurology (EAN) and the Peripheral Nerve Society (PNS) construc …
To develop an evidence-based guideline for the diagnosis and treatment of GBS, using Grading of Recommendations, Assessment, Development and …
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Current Therapies and Future Approaches.
Svačina MKR, Lehmann HC. Svačina MKR, et al. Curr Pharm Des. 2022;28(11):854-862. doi: 10.2174/1381612828666220325102840. Curr Pharm Des. 2022. PMID: 35339172 Review.
Despite various established therapies and the current development of novel therapeutics, treatment of CIDP remains challenging due to an heterogeneous disease course and the lack of surrogate parameters to predict the risk of clinical deterioration. ...
Despite various established therapies and the current development of novel therapeutics, treatment of CIDP remains challenging due to an het …
Peripheral neuropathies.
Hanewinckel R, Ikram MA, Van Doorn PA. Hanewinckel R, et al. Handb Clin Neurol. 2016;138:263-82. doi: 10.1016/B978-0-12-802973-2.00015-X. Handb Clin Neurol. 2016. PMID: 27637963 Review.
Immune-Mediated Neuropathies.
Gwathmey KG, Smith AG. Gwathmey KG, et al. Neurol Clin. 2020 Aug;38(3):711-735. doi: 10.1016/j.ncl.2020.03.008. Epub 2020 Jun 11. Neurol Clin. 2020. PMID: 32703478 Review.
The immune-mediated neuropathies are a broad category of diseases differentiated by time course, affected nerve fibers, and disease associations. This article spans the common, well-defined inflammatory demyelinating polyradiculoneuropathies (Guillain-Barre syndrome and ch …
The immune-mediated neuropathies are a broad category of diseases differentiated by time course, affected nerve fibers, and disease a …
Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.
Oaklander AL, Lunn MP, Hughes RA, van Schaik IN, Frost C, Chalk CH. Oaklander AL, et al. Cochrane Database Syst Rev. 2017 Jan 13;1(1):CD010369. doi: 10.1002/14651858.CD010369.pub2. Cochrane Database Syst Rev. 2017. PMID: 28084646 Free PMC article. Review.
Methotrexate may not be of benefit and IFN beta-1a is probably not of benefit.We need further research to identify predictors of response to different treatments and to compare their long-term benefits, safety and cost-effectiveness. ...
Methotrexate may not be of benefit and IFN beta-1a is probably not of benefit.We need further research to identify predictors of resp …
Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG?
Allen JA, Gelinas DF, Freimer M, Runken MC, Wolfe GI. Allen JA, et al. J Neurol Sci. 2020 Jan 15;408:116497. doi: 10.1016/j.jns.2019.116497. Epub 2019 Nov 9. J Neurol Sci. 2020. PMID: 31765922 Free article. Review.
Expeditious diagnosis and treatment of CIDP early in the disease course is critical such that irreversible disability can be avoided. ...
Expeditious diagnosis and treatment of CIDP early in the disease course is critical such that irreversible disability can be avoided. …
Rituximab in refractory chronic inflammatory demyelinating polyneuropathy.
Muley SA, Jacobsen B, Parry G, Usman U, Ortega E, Walk D, Allen J, Pasnoor M, Varon M, Dimachkie MM. Muley SA, et al. Muscle Nerve. 2020 May;61(5):575-579. doi: 10.1002/mus.26804. Epub 2020 Jan 21. Muscle Nerve. 2020. PMID: 31922613
A placebo-controlled study to assess the effectiveness of rituximab therapy in CIDP with and without nodal antibodies is required to identify disease markers that predict responsiveness....
A placebo-controlled study to assess the effectiveness of rituximab therapy in CIDP with and without nodal antibodies is required to identif …
Diagnosis, treatment and prognosis of Guillain-Barre syndrome (GBS).
van Doorn PA. van Doorn PA. Presse Med. 2013 Jun;42(6 Pt 2):e193-201. doi: 10.1016/j.lpm.2013.02.328. Epub 2013 Apr 28. Presse Med. 2013. PMID: 23628447 Review.
Pain can also be very confusing in making the diagnosis, especially when it precedes the onset of weakness. Advances in prognostic modelling resulted in the development of a simple prognostic scale that predicts the chance for artificial ventilation, already …
Pain can also be very confusing in making the diagnosis, especially when it precedes the onset of weakness. Advances in prognostic mo …
Acute/chronic inflammatory polyradiculoneuropathy.
Miranda C, Brannagan TH 3rd. Miranda C, et al. Handb Clin Neurol. 2023;195:619-633. doi: 10.1016/B978-0-323-98818-6.00026-1. Handb Clin Neurol. 2023. PMID: 37562890 Review.
Autoimmune neuropathy may present acutely or with a more progressive and/or relapsing and remitting course. Acute inflammatory neuropathy or Guillain-Barre syndrome (GBS) has variable presentations but by far the most common is acute inflammatory demyelinating polyradiculo …
Autoimmune neuropathy may present acutely or with a more progressive and/or relapsing and remitting course. Acute inflammatory neurop …
Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database.
Doneddu PE, Cocito D, Manganelli F, Fazio R, Briani C, Filosto M, Benedetti L, Mazzeo A, Marfia GA, Cortese A, Fierro B, Jann S, Beghi E, Clerici AM, Carpo M, Schenone A, Luigetti M, Lauria G, Antonini G, Rosso T, Siciliano G, Cavaletti G, Liberatore G, Santoro L, Peci E, Tronci S, Ruiz M, Cotti Piccinelli S, Toscano A, Mataluni G, Piccolo L, Cosentino G, Sabatelli M, Nobile-Orazio E; Italian CIDP Database study group. Doneddu PE, et al. J Neurol Neurosurg Psychiatry. 2019 Feb;90(2):125-132. doi: 10.1136/jnnp-2018-318714. Epub 2018 Oct 8. J Neurol Neurosurg Psychiatry. 2019. PMID: 30297520 Free article.
CONCLUSIONS: The proportion of patients with atypical CIDP varies during the disease course. DADS and LSS have a less frequent response to intravenous immunoglobulin compared with typical CIDP, raising the possibility of a different underlying pathogenetic mechanism....
CONCLUSIONS: The proportion of patients with atypical CIDP varies during the disease course. DADS and LSS have a less frequent respon …
476 results